WuXi XDC Cayman: Record revenue and backlog growth, with robust outlook and expanding global capacityQuartr·1 day ago, 10:47 AM022680.00%018750.00%
From Energy Shifts to Crypto ETFs: Assessing Hong Kong's Niche MarketsGlobal Report·1 day ago, 05:11 AM010880.00%017830.00%
TOT Biopharm FY26 H1 net loss swings to RMB 59 million; revenue drops 49.7% to RMB 246 millionPUBT·Aug 21 at 06:47 AM018750.00%
The Hong Kong Market's "Leftover" Bin: Who's Faking It and Who's Real?Global Report·Aug 19 at 04:44 AM019510.00%018750.00%
Margin Defense Overrides Expansion as Hong Kong Consumer and Property Sectors AdjustGlobal Report·Aug 6 at 04:14 AM023140.00%011790.00%
Nomura Cuts WUXI XDC TP to HKD82.6 on Adverse FX Impact on EarningsAASTOCKS News·Jul 26 at 10:47 PM018750.00%022680.00%
Liquidity spillovers trigger a structural repricing in Hong Kong's unclassified cornersGlobal Report·Jul 25 at 04:14 AM096000.00%013410.00%
BOCOM International Cuts WUXI XDC TP to HKD80; Earnings Still Expected to Deliver Strong Growth Amid FX VolatilityAASTOCKS News·Jul 15 at 01:40 AM018750.00%022680.00%
BioDlink Sets August Board Meeting to Approve Interim 2026 ResultsTip Ranks·Jul 10 at 04:40 AM018750.00%
WuXi XDC Unit BioDlink Signs RMB19 Million Monoclonal Antibody Manufacturing Deal With WuXi BiologicsTip Ranks·Jun 16 at 06:00 PM022680.00%022690.00%
BioDlink Shareholders Approve CDMO Master Agreement With WuXi XDCTip Ranks·Jun 11 at 07:10 AM018750.00%
